EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis

Dipeptidyl-Peptidase-4-Inhibitoren und Herzinsuffizienz-Ereignisse bei erwachsenen Patient:innen mit Typ-2-Diabetes mellitus: systematische Übersicht und Metaanalyse

Shishir Nepal iD, Shiva Prasad Nepal iD

Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)

DOI: 10.1002/edm2.70316 ↗

Auf einen Blick

Die Metaanalyse von 29 Studien mit 67.873 Patient:innen fand keinen statistisch signifikanten Zusammenhang zwischen DPP-4-Inhibitoren und Herzinsuffizienz-Ereignissen. Für Saxagliptin zeigte sich in der Subgruppenanalyse ein erhöhtes Risiko.

Fragestellung

Sind DPP-4-Inhibitoren bei erwachsenen Patient:innen mit Typ-2-Diabetes mit Herzinsuffizienz-Ereignissen verbunden?

Methode

Systematische Übersicht und Metaanalyse von RCTs; Suche in PubMed/Medline, DOAJ, MDPI, Google Scholar und clinicaltrails.gov Ende Januar 2026; RoB-2 und GRADE; PRISMA 2020.

Ergebnisse

29 eingeschlossene Studien; gepoolt 67.873 Patient:innen. Herzinsuffizienz: RR 1,06 (95 %-KI 0,94–1,12). In der Subgruppenanalyse war Saxagliptin mit erhöhtem Risiko assoziiert.

Einschränkungen

Die Autoren nennen mehrere Limitationen, ohne sie im Abstract zu spezifizieren.

Schlussfolgerung der Autor:innen

Die Ergebnisse sollten wegen mehrerer Limitationen der Studie mit Vorsicht interpretiert werden.

Kernaussagen

  • Kein statistisch signifikanter Gesamtzusammenhang zwischen DPP-4-Inhibitoren und Herzinsuffizienz
  • RR 1,06 (95 %-KI 0,94–1,12)
  • Saxagliptin zeigte in der Subgruppenanalyse ein erhöhtes Risiko

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 19.08.2026. Verfasst von Shishir Nepal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, Pokhara Academy of Health Sciences, Pokhara, Gandaki, Nepal. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Heart Failure, Diabetes Mellitus, Type 2. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

DPP‐4 inhibitors use has been reported to cause heart failure events in patients with type‐2 diabetes. The FDA had also issued warnings concerning increased risk of heart failure events for alogliptin, saxagliptin and their combination with metformin.

Methods

Randomized controlled trials (RCTs) involving adult patients with type‐2 diabetes patients with or without history of cardio‐vascular disorders were included in the review. Cohort studies, case–control studies and other non‐RCTs, and studies involving paediatric patients were excluded. Data bases searched were PubMed/Medline, DOAJ, MDPI, Google Scholar and clinicaltrails.gov . The search was conducted in late January of 2026. Risk of bias was assessed using RoB‐2 tool for RCTs. Individual study outcomes were tabulated and summary measure was synthesized by meta‐analysis under random effect model; GRADE certainty of evidence was used; sub‐group analysis based on individual DPP‐4 inhibitors, follow‐up duration and placebo or other controls was done; systematic review was done under PRISMA 2020 Guidelines.

Results

The meta‐analysis was done under random effect computation model for all 29 included studies. The analysis for total of pooled 67,873 patients showed statistically insignificant association between the use of DPP‐4 inhibitors and heart failure with Risk Ratio (RR) = 1.06, 95% Confidence Interval (CI) 0.94–1.12. Sub‐group analysis found significant association of saxagliptin use with increased heart failure risk.

Conclusion

Results should be interpreted with caution because of several limitations of the study. Trial Registration PROSPERO, CRD420261288081

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsHeart FailureDiabetes Mellitus, Type 2HumansAdultRandomized Controlled Trials as TopicAdamantaneDipeptides

Stichwörter der Autor:innen

DPP‐4 inhibitorsdipeptidyl peptidase‐4 inhibitorsheart failurelinagliptinsaxagliptinsitagliptintype‐2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorssaxagliptinAdamantaneDipeptides

Autor:innen und Institutionen

  • Faculty of Medical Sciences, Pokhara Academy of Health Sciences, Pokhara, Gandaki, Nepal.
  • Faculty of Management, Tribhuvan University, Kirtipur, Kathmandu, Nepal.

ORCID-Profile: Shishir Nepal, Shiva Prasad Nepal

Zitieren

APA

Nepal, S., & Nepal, S. P. (2026). Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70316

Vancouver

Nepal S, Nepal SP. Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70316

BibTeX
@article{Nepal2026,
  author = {Nepal, Shishir and Nepal, Shiva Prasad},
  title = {Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/edm2.70316}
}
Kostenlos starten →